Intralesional Triamcinolone Acetonide Injection as a Treatment for Granulomatous Tissue on Tracheocutaneous Stoma

Background and Objectives The aim of this study was to confirm the effect of intralesional triamcinolone acetonide injections (TRIAM) to treat granulomatous tissue surrounding the tracheostomy stoma.Subjects and Method We reviewed and documented the medical charts of 20 patients who were administered with TRIAM to treat granulomatous tissue surrounding the tracheostomy stoma from January 2018 to June 2019 were. The surface area of the granulomatous tissue was measured using Image J. The differences between the area of the granulomatous tissue after conventional treatment and after TRIAM on the same patient were compared.Results A total of 20 patients consisting of 12 males and 8 females were included, with the patients’ average age being 60.0±14.3 years. The initial surface area of granulation tissue was 1.266±0.449 cm<sup>2</sup>, and 1.243±0.432 cm<sup>2</sup> after conventional treatment, showing no statistically significant difference in the tissue area (<i>p</i>=0.143). The pre-injection surface area of granulation tissue was 1.243±0.432 cm<sup>2</sup>, and the area on the 7th day after the third injection was 0.477±0.217 cm<sup>2</sup>, showing a significant difference (<i>p</i><0.001).Conclusion Compared to the conventional treatment, the surface area of granulomatous tissue surrounding the tracheostomy stoma significantly decreased after being treating with TRIAM. This finding suggests the effectiveness of TRIAM as a treatment of granulomatous tissue surrounding the tracheostomy stoma without complications such as bleeding.